The Fund Grade · free · no account needed
What grade does LRND get?
Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.
Fundprints Fund Grade · as of 2026-09-01
NYLI U.S. Large Cap R&D Leaders ETF
#57 of 440 graded active funds · blend · large segment peer group
The point · specialist footprint
LRND puts more of its book behind proven specialists than 91% of graded funds.
Bottom 20%
Bottom 40%
Middle
Top 40%
● Top 20%
That has mattered: over the past 2.7 years, funds on this rung beat bottom-rung funds by about 3.8 points per quarter, and beat the S&P in 43% of fund-quarters versus their 22%. The evidence argues this fund earns its seat.
2,825 graded funds · 2.7 years of filings, measured as they were published · evidence, not advice
You pay 0.14% a year for a A.
The grade scores this fund's specialist share — the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.
Conviction exposure
45.9%
of the book in specialist-converged names
Late-stage weight
14.7%
of the book in Crowded or Fading names
Active share
80.6%
how far it strays from the index
The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.
Inside the book — top names by stage · as of 2026-09-09
We email you the day it crosses 50% crowded, and where you stand every month.
Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.
The read · what to do with it
LRND earns an A grade and ranks 57 of 440 funds, with specialists holding nearly 46% of the book at just 0.14% annually. The fund is early in AMZN, AMAT, and VRT, which is the strongest signal here. Watch the fading side though, AVGO alone sits at 4.5% and specialists are leaving that position.
→ Monitor AVGO closely given its 4.5% weight and Fading stage, as specialist exits at that size can drag performance meaningfully.
→ The Early Conviction reads on AMZN and AMAT suggest the fund is genuinely ahead of consensus there, worth tracking whether those weights grow.
Support leaving these positions
Read from today's disclosed book. Evidence, not advice.
The evidence base updates this week.
The specialists — not the whales — are already positioned for what comes next. Stop finding out last.
Create your free accountNo card required · open the feed in 30 seconds